Matthew Weston

Stock Analyst at UBS

(0.44)

# 3,976

Out of 4,827 analysts

3

Total ratings

n/a

Success rate

-3.49%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General

Stocks Rated by Matthew Weston

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NVS Novartis AG	Downgrades: Neutral	n/a	$110.55	-	1	Feb 13, 2025
	AZN AstraZeneca	Upgrades: Buy	n/a	$70.26	-	2	Feb 13, 2025

Novartis AG

Feb 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $110.55

Upside: -

AstraZeneca

Feb 13, 2025

Upgrades: Buy

Price Target: n/a

Current: $70.26

Upside: -